Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:
Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
Jianfeng Pharmaceuticals ranks among the top 50 creative enterprises in Jinhua
News from our newspaper April 26 is World Intellectual Property Day. Jinhua City released the list of "Top 50 Creative Enterprises" for the first time. Jianfeng Pharmaceutical Company entered the list and ranked second among the enterprises in Jinhua Development Zone. The selection of creative enterprises, the enterprise holds the effective invention patent as the main indicator. Over the years, Jianfeng Pharmaceutical Co., Ltd. has taken "intellectual property rights help enterprise development, and scientific and technological innovation creates a century-old peak" as the company's intellectual property policy. It has actively cooperated with China Pharmaceutical University, Sichuan Institute of Antibiotic Industry, Zhejiang University of Technology, Xiamen University and other units to build a scientific research and innovation platform integrating production, learning and research, and flexibly introduced Academician Wang Guangji and Academician Shan Weiguang with the chief scientist system, according to the direction of enterprise development strategy to carry out scientific research work, and achieved fruitful results. In 2019, Spike Pharmaceuticals applied for 2 invention patents and obtained 5 patent authorizations, including 1 invention. By the end of 2019, Spike Pharmaceuticals had obtained a total of 37 patents (including 2 PCT patents), of which 28 were inventions. In recent years, in order to better integrate with the international market, Jianfeng Pharmaceutical has made a complete patent layout for the new drug DPT under development, and has applied for patent protection in multiple countries through the PCT application channel for core patents, and finally in the high-level United States. And Japan was authorized to lay a solid foundation for the product to enter these two overseas high-end markets. At the same time, around the core patent, applied for the preparation, crystal type patent and obtained the invention patent authorization 5. In addition, pharmaceutical companies have also developed patents for other varieties under research.
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-31
Jinhua chain pharmacy big "physical examination" peak pharmacy got an "A"
Jinhua City Market Supervision Bureau recently announced the results of drug quality credit rating of drug retail chain enterprises in the city, and Jianfeng Pharmacy was rated as A in this "physical examination. According to the spirit of the document "Implementation Plan for Drug Quality Credit Classification Management of Jinhua Drug Trading Enterprises" and in accordance with relevant evaluation standards, Jinhua Market Supervision Bureau evaluated the 2019 drug quality credit rating of 34 drug retail chain enterprises (headquarters) in the city that met the evaluation requirements, involving 1498 stores. The score combines the daily supervision and inspection of chain headquarters, GSP certification inspection, administrative punishment and other drug quality-related information with the credit rating results of subordinate stores, and divides 100 into basic points, and forms the final score after adding and subtracting points according to the evaluation system. Those with 93 points or above are grade A (trustworthy enterprises),85-92 are grade B (basically trustworthy enterprises), and 80-84 are grade C (slightly dishonest enterprises), A score below 80 is Grade D (seriously dishonest enterprise). It is understood that the market supervision department will enter the enterprise credit rating evaluation results into the drug safety credit management system of Zhejiang Food and Drug Administration and Jinhua intelligent supervision and supervision platform to establish enterprise credit files. According to the credit rating evaluation results over the years, classified management will be carried out, and low-grade enterprises will increase the frequency of inspection. The "credit rating publicity board of drug trading enterprises" will be hung in the retail drugstore hall, and the evaluation results of the store will be publicized every year, let the people intuitively understand the credit situation of the store. At the same time, A- level enterprises are also the threshold for obtaining the qualification of designated medical insurance units, all kinds
2020
07-31
Daye Mayor to Daye Peak Research Issued "Anti-Epidemic" Donation Certificate
On the morning of March 26, Daye City Deputy Secretary, Mayor Zhou Jun and Daye City Economic and Information Bureau, Security Town and other responsible persons visited Daye Peak Cement Company to understand the epidemic prevention and control and resumption of production, and on behalf of the Daye City Charity Federation issued a certificate of donation of epidemic prevention and control materials. Accompanied by Zhang Fengliang, deputy general manager of the group company and general manager of Daye Peak, Yuan Xianming, executive deputy general manager of Daye Peak, and others, Zhou Jun and his entourage went to the work site of Daye Peak to learn about the resumption of work and production. Zhang Fengliang introduced the progress of the upgrading and transformation of the grate cooler, the transformation of the kiln cylinder and the technical transformation of the cement mill system, and made a detailed report on the production and technical transformation organization of the enterprise during the epidemic, and expressed his gratitude to Daye City and Baoan Town for their help to Daye Peak during this period. Mayor Zhou Jun spoke highly of the production and technological transformation organization during the Daye peak epidemic, believing that this is a model of combining epidemic prevention and control with enterprise production and technological transformation organization. At the same time, Zhou Jun expressed his affirmation and gratitude to Daye Peak for donating money and goods to Daye City in the first time after the outbreak of the epidemic, and issued a donation certificate and a letter of thanks on behalf of the Daye City Charity Federation. Hubei Province epidemic prevention and control headquarters has recently issued a step-by-step "unsealing" notice in Hubei Province, how to fully resume work and production as soon as possible is an important issue facing Daye peak. Zhang Fengliang reported to Zhou Jun and his party on the current practical difficulties. Mayor Zhou Jun asked
2020
07-31
Since the resumption of work after the Spring Festival, on March 17, Yu Jian, general manager of the group company, went to the site of the Huangping project in Guizhou to guide the construction progress of the Huangping project. During his stay in Huang Ping, General Manager Yu Jianhong visited the construction site of the project carefully, interviewed the project leaders of each construction unit respectively, sorted out the installation time of each unit of civil engineering and the completion time of each equipment installation, and required each construction unit to push forward the project progress in strict accordance with the agreed time node. At the same time, in view of the current epidemic prevention and control work and on-site construction safety management, Yu Jianhong also further put forward requirements, hoping to achieve "zero infection, zero accident". On the 18th, Yu Jianhong also conducted a research on the market in Kaili and other surrounding areas together with the marketing personnel of Guizhou Jianfeng Marketing Department, and put forward guiding opinions on the cement sales advertising plan and the division of cement sales areas. On this business trip, Yu Jianhong also specially brought Jinhua specialty ham and crisp cakes to the project team members, which were welcomed by everyone. (Lei Yuan)
2020
07-30
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page